Q
QurAlis
Biotech company focused on developing precision solutions to cure amyotrophic lateral sclerosis
About QurAlis
QurAlis is a pioneering biotech startup that operates in the healthcare sector, specifically focusing on neurodegenerative diseases. The company is on a mission to develop effective precision medicines that can change the course of diseases like Amyotrophic lateral sclerosis (ALS), Frontotemporal dementia (FTD), and other neurodegenerative conditions. ALS, also known as Lou Gehrig’s disease, is a progressive disease that affects nerve cells in the brain and spinal cord, leading to loss of muscle control.
QurAlis' business model revolves around its proprietary and investigative platforms, QR43™ and FlexASO™. The QR43™ platform is dedicated to discovering and developing precision therapies for diseases related to TDP-43, a protein that plays a critical role in ALS. The FlexASO™ platform is a custom tool designed to tackle the spectrum of diseases that define ALS and other similar conditions.
The company's revenue generation strategy is based on the development and commercialization of these therapeutic candidates. QurAlis aims to serve a niche market of patients suffering from neurodegenerative diseases, particularly those with ALS and FTD.
In summary, QurAlis is a healthcare startup with a focus on neurodegenerative diseases, using innovative platforms to develop precision medicines. Its business model is centered on the development and commercialization of these therapies, serving a market of patients with ALS, FTD, and other similar conditions.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2016
- Headquarters
- Cambridge, United States
- Employees
- 86
- Open positions
- None listed
- Dealroom signal
- 67.5/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, DNA, Genetics and genomics, Genome Engineering, Biotech and Pharma, Hard Tech, proteomics, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | Sep 2025 | $25M | $440M | Undisclosed | ↗ |
| SERIES BOther financing | Mar 2023 | $88M | $352M | Inkef · Polaris Partners · Dolby Family Ventures · Amgen Ventures | ↗ |
Growth signals
Latest recorded traffic for QurAlis is 5K monthly website visits, down 12.3% over the last three months. QurAlis's team declined 8.5% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed4 investors entered at this stage
Amgen Ventures
Mission BioCapital
MP Healthcare Venture Management
Viva Vision Biotech
Series A12 investors entered at this stage
Inkef
SV Health Investors
Polaris Partners
Mitsui Global Investment
Dolby Family Ventures
Droia Oncology Ventures
Dementia Discovery Fund
EQT Life Sciences
Sanofi Ventures
Mission Bay Capital
ALS Investment Fund- SBSanford Biosciences
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about QurAlis on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See QurAlis’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.